Tabrecta Archives -

Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for

Novartis bags FDA okay for BRAF-positive tumour combination

https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/

The UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small

Merck’s targeted lung cancer drug tepotinib wins early access in UK

https://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/

Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer

FDA starts quick review of Merck’s MET-targeting lung cancer drug

https://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/

Tabrecta